Melanotan 1 vs Melanotan 2: A Research Comparison

Melanotan 1 and Melanotan 2 are synthetic analogs of alpha-melanocyte-stimulating hormone (alpha-MSH). Labs use them as reference agonists in melanocortin receptor pharmacology. They are often discussed together. Yet they differ in backbone shape, receptor selectivity, and molecular weight. They also suit different kinds of signaling questions. This comparison sets the two side by side strictly for lab research.

How do Melanotan 1 and Melanotan 2 differ in structure?

Melanotan 1 is a straight-chain peptide, while Melanotan 2 is a ring-shaped one.

Melanotan 1 is also listed as afamelanotide, CUV1647, or [Nle4-D-Phe7]-alpha-MSH. It is a linear peptide of 13 amino acids built on the native alpha-MSH sequence. Two swaps define it:

• Norleucine at position 4.
• D-phenylalanine at position 7.

These swaps are linked to better resistance to enzyme breakdown. They are also linked to stronger receptor activity than the native hormone. That is why the analog has stayed a lasting lab reference. It was first described as a highly potent alpha-melanotropin with very long biological activity.

Melanotan 2 takes a different structural route. It is a ring-shaped peptide of seven amino acids. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. A lactam bridge locks the core sequence into a ring.

Locking the backbone limits how freely the active region can move. The ring form is linked to better stability and longer receptor activity than native alpha-MSH.

The mass gap follows from these designs:

• Melanotan 1: formula C78H111N21O19, about 1646.85 g/mol, CAS 75921-69-6, PubChem 16154217.
• Melanotan 2: formula C50H69N15O9, about 1024.18 g/mol, CAS 121062-08-6, PubChem 92432.

Any molarity calculation or dilution series must account for that gap of about 620 g/mol. Equal masses of the two powders are not equal numbers of molecules.

How does receptor selectivity differ between the two?

Selectivity is the most important difference between the two analogs.

Melanotan 1 is studied as an agonist that leans toward the melanocortin-1 receptor, MC1R. This is the subtype most closely tied to pigment biology in melanocyte models. The preference is relative, not absolute. But it is strong enough that the compound is seen as the more targeted of the pair.

Melanotan 2 is described instead as a non-selective agonist. It acts on MC1R, MC3R, MC4R, and MC5R. It does not isolate one subtype. It activates the family broadly. That makes it a useful reference when the subject of study is the whole receptor family as a system, not a single part of it.

• Class: linear alpha-MSH analog versus ring-shaped alpha-MSH analog.
• Structure: 13-amino-acid linear peptide versus seven-amino-acid ring peptide.
• Selectivity: leans toward MC1R versus non-selective across MC1R, MC3R, MC4R, and MC5R.
• Research focus: pigment and photoprotection pathways versus broad melanocortin signaling.
• Molecular weight: about 1646.85 g/mol versus 1024.18 g/mol.

What downstream signaling is reported in model systems?

At MC1R, both analogs use the same standard second-messenger route. In model systems, receptor activity is linked to activation of adenylate cyclase and the cyclic AMP cascade that follows. In melanocyte cultures, this cascade has been studied for its link to eumelanin production.

Eumelanin is studied as a pigment that protects against light. So this pathway also lets labs probe the link between MC1R activation and pigment-based cell protection under test ultraviolet stress.

The two differ in everything beyond MC1R. Melanotan 2 also acts on MC3R and MC4R, found mainly in the brain, and on MC5R, found in other tissues. So a study using it measures a mix of several receptor signaling arms at once.

Melanotan 1 gives a cleaner readout at MC1R. That matters when off-target melanocortin signaling would confound the endpoint.

The Melanotan 1 mechanism of action and Melanotan 2 mechanism of action articles walk through each cascade in more detail.

Many labs therefore run the two in parallel. Comparative melanocortin pharmacology is a documented research use for both. It benchmarks a selective analog against a non-selective one and against native alpha-MSH.

How do stability and persistence affect time-course design?

Both compounds were designed to outlast native alpha-MSH, which shapes study timing.

• In Melanotan 1, the unnatural residues at positions 4 and 7 slow enzyme clearance.
• In Melanotan 2, the lactam-bridged ring does similar work by stiffening the backbone.

Both changes are reported to extend receptor activity compared with the native hormone. That is why either one is preferred over alpha-MSH itself when an assay needs a stable agonist over a long incubation.

That persistence has design consequences. A longer activity window widens the useful gap between sampling points. It makes time-dependent behavior easier to see. But washout and control conditions must then be planned on purpose, not assumed.

Findings from either analog should be read as observations that depend on concentration and time, inside a defined model. They do not describe a fixed mechanism.

Which analog fits which research question?

The endpoint decides the choice.

Some questions are limited to MC1R, pigment production, or photoprotection markers in melanocyte cultures. For these, Melanotan 1 is the better probe. Family-wide activation would add noise.

Other questions cover the melanocortin receptor family as a whole, comparisons across subtypes, or signaling arms beyond MC1R. For these, Melanotan 2 is the compound designed for that breadth.

Puritide Research supplies both, along with MT-2. MT-2 is another name for the same ring-shaped peptide, also written MT-II. So catalog searches work whichever naming style a protocol uses. All three ship as sealed 10 mg vials of white freeze-dried powder at 99% purity or better.

How are they handled, tested, and documented?

Handling needs are essentially the same for both analogs. Both come as solid white freeze-dried powder in sealed glass vials.

• Store at or below 25 degrees Celsius, away from heat, light, and moisture.
• For long storage, keep the material freeze-dried and chilled or frozen.
• Hold conditions steady across the study, so storage history never becomes a variable in the data.

Puritide Research sources these materials and has every batch tested by independent third-party labs. Each batch ships with a certificate of analysis. It covers purity by HPLC or reverse-phase chromatography, identity by mass spectrometry, and lot number, test date, and method details.

Record lot numbers and storage conditions alongside results. Keep the batch paperwork for tracing. Follow institutional standard procedures and wear suitable protective gear.

Common research questions

What is the structural difference between Melanotan 1 and Melanotan 2?

Melanotan 1 is a linear 13-amino-acid alpha-MSH analog with norleucine and D-phenylalanine swaps. Melanotan 2 is a ring-shaped seven-amino-acid peptide. Its lactam bridge locks the core sequence into a ring. The ring shape is linked to its broader receptor activity.

Why does receptor selectivity matter in study design?

An agonist that leans toward MC1R isolates a single subtype. So pigment pathway endpoints are not muddied by signaling at other receptors. A non-selective agonist activates MC1R, MC3R, MC4R, and MC5R together on purpose. That suits questions about the receptor family as a system.

Are MT-2 and Melanotan 2 the same compound?

Yes. MT-2, MT-II, and Melanotan-2 are all names for the same ring-shaped alpha-MSH analog. Puritide Research lists the material under both names, so protocols written with either name find the correct vial.

For research use only. Melanotan 1 and Melanotan 2 are laboratory research materials. They are not approved for human or veterinary use, not for diagnostic or therapeutic application, and nothing above is medical advice or a claim of benefit. All statements describe observations reported in in vitro assays and animal research models.